A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

Science Translational Medicine

Volumn 7, Issue 289, 2015, Pages

  Chichili, Gurunadh R ^a   Huang, Ling ^a   Li, Hua ^a   Burke, Steve ^a   He, Leilei ^a   Tang, Qin ^a   Jin, Linda ^a   Gorlatov, Sergey ^a   Ciccarone, Valentina ^a   Chen, Francine ^a   Koenig, Scott ^a   Shannon, Michele ^a   Alderson, Ralph ^a   Moore, Paul A ^a   Johnson, Syd ^a   Bonvini, Ezio ^a  

^a Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD123 ANTIGEN; CD3 ANTIGEN; MGD 006; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; LEUKOCYTE ANTIGEN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DOSE RESPONSE; DRUG BINDING; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MACACA FASCICULARIS; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT DURATION; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; BONE MARROW; CELL DEATH; CELL PROLIFERATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; METABOLISM; PATHOLOGY; PROTEIN ENGINEERING; SECRETION (PROCESS);

ANIMALS; ANTIGENS, CD; ANTIGENS, CD3; BONE MARROW; CELL DEATH; CELL PROLIFERATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMATOPOIESIS; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MACACA FASCICULARIS; MALE; MICE; PROTEIN BINDING; PROTEIN ENGINEERING; T-LYMPHOCYTES;

EID: 84930154086     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa5693     Document Type: Article

References (38)

1. L. Muñoz, J. F. Nomdedéu, O. López, M. J. Carnicer, M. Bellido, A. Aventín, S. Brunet, J. Sierra, Interleukin-3 receptor a chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86, 1261-1269 (2001).
2. U. Testa, E. Pelosi, A. Frankel, CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark. Res. 2, 4 (2014).
3. + blasts are predictive of an adverse outcome in acute myeloid leukemia: A Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study. Haematologica 96, 1792-1798 (2011).
4. C. T. Jordan, D. Upchurch, S. J. Szilvassy, M. L. Guzman, D. S. Howard, A. L. Pettigrew, T. Meyerrose, R. Rossi, B. Grimes, D. A. Rizzieri, S. M. Luger, G. L. Phillips, The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777-1784 (2000).
5. L. Jin, E. M. Lee, H. S. Ramshaw, S. J. Busfield, A. G. Peoppl, L. Wilkinson, M. A. Guthridge, D. Thomas, E. F. Barry, A. Boyd, D. P. Gearing, G. Vairo, A. F. Lopez, J. E. Dick, R. B. Lock, Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5,31-42 (2009).
6. D. A. Pollyea, J. A. Gutman, L. Gore, C. A. Smith, C. T. Jordan, Targeting acute myeloid leukemia stem cells: A review and principles for the development of clinical trials. Haematologica 99, 1277-1284 (2014).
7. S. Z. He, S. Busfield, D. S. Ritchie, M. S. Hertzberg, S. Durrant, I. D. Lewis, P. Marlton, A. J. McLachlan, I. Kerridge, K. F. Bradstock, G. Kennedy, A. W. Boyd, T. M. Yeadon, A. F. Lopez, H. S. Ramshaw, H. Iland, S. Bamford, M. Barnden, M. DeWitte, R. Basser, A. W. Roberts, A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk. Lymphoma 1-10 (2014).
8. E. I. Korpelainen, J. R. Gamble, M. A. Vadas, A. F. Lopez, IL-3 receptor expression, regulation and function in cells of the vasculature. Immunol. Cell Biol. 74, 1-7 (1996).
9. M. Klinger, C. Brandl, G. Zugmaier, Y. Hijazi, R. C. Bargou, M. S. Topp, N. Gökbuget, S. Neumann, M. Goebeler, A. Viardot, M. Stelljes, M. Brüggemann, D. Hoelzer, E. Degenhard, D. Nagorsen, P. A. Baeuerle, A. Wolf, P. Kufer, Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119, 6226-6233 (2012).
10. M. S. Topp, N. Gökbuget, G. Zugmaier, E. Degenhard, M. E. Goebeler, M. Klinger, S. A. Neumann, H. A. Horst, T. Raff, A. Viardot, M. Stelljes, M. Schaich, R. Köhne-Volland, M. Brüggemann, O. G. Ottmann, T. Burmeister, P. A. Baeuerle, D. Nagorsen, M. Schmidt, H. Einsele, G. Riethmüller, M. Kneba, D. Hoelzer, P. Kufer, R. C. Bargou, Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120, 5185-5187 (2012).
11. M. S. Topp, P. Kufer, N. Gökbuget, M. Goebeler, M. Klinger, S. Neumann, H. A. Horst, T. Raff, A. Viardot, M. Schmid, M. Stelljes, M. Schaich, E. Degenhard, R. Köhne-Volland, M. Brüggemann, O. Ottmann, H. Pfeifer, T. Burmeister, D. Nagorsen, M. Schmidt, R. Lutterbuese, C. Reinhardt, P. A. Baeuerle, M. Kneba, H. Einsele, G. Riethmüller, D. Hoelzer, G. Zugmaier, R. C. Bargou, Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498 (2011).
12. S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. Chew, V. E. Gonzalez, Z. Zheng, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, S. R. Rheingold, A. Shen, D. T. Teachey, B. L. Levine, C. H. June, D. L. Porter, S. A. Grupp, Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
13. S. Johnson, S. Burke, L. Huang, S. Gorlatov, H. Li, W. Wang, W. Zhang, N. Tuaillon, J. Rainey, B. Barat, Y. Yang, L. Jin, V. Ciccarone, P. A. Moore, S. Koenig, E. Bonvini, Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 399, 436-449 (2010).
14. P. A. Moore, W. Zhang, G. J. Rainey, S. Burke, H. Li, L. Huang, S. Gorlatov, M. C. Veri, S. Aggarwal, Y. Yang, K. Shah, L. Jin, S. Zhang, L. He, T. Zhang, V. Ciccarone, S. Koenig, E. Bonvini, S. Johnson, Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117, 4542-4551 (2011).
15. J. R. Litowski, R. S. Hodges, Designing heterodimeric two-stranded α-helical coiled-coils. Effects of hydrophobicity and α-helical propensity on protein folding, stability, and specificity. J. Biol. Chem. 277, 37272-37279 (2002).
16. M. S. Kung Sutherland, R. B. Walter, S. C. Jeffrey, P. J. Burke, C. Yu, H. Kostner, I. Stone, M. C. Ryan, D. Sussman, R. P. Lyon, W. Zeng, K. H. Harrington, K. Klussman, L. Westendorf, D. Meyer, I. D. Bernstein, P. D. Senter, D. R. Benjamin, J. G. Drachman, J. A. McEarchern, SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122, 1455-1463 (2013).
17. E. K. Keeton, K. McEachern, K. S. Dillman, S. Palakurthi, Y. Cao, M. R. Grondine, S. Kaur, S. Wang, Y. Chen, A. Wu, M. Shen, F. D. Gibbons, M. L. Lamb, X. Zheng, R. M. Stone, D. J. Deangelo, L. C. Platanias, L. A. Dakin, H. Chen, P. D. Lyne, D. Huszar, AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 123, 905-913 (2014).
18. K. L. Gutbrodt, G. Casi, D. Neri, Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol. Cancer Ther. 13, 1772-1776 (2014).
19. H. K. Lee, H. W. Kim, I. Y. Lee, J. Lee, J. Lee, D. S. Jung, S. Y. Lee, S. H. Park, H. Hwang, J. S. Choi, J. H. Kim, S. W. Kim, J. K. Kim, J. Cools, J. S. Koh, H. J. Song, G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood 123, 2209-2219 (2014).
20. R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler, H. Einsele, C. Brandl, A. Wolf, P. Kirchinger, P. Klappers, M. Schmidt, G. Riethmüller, C. Reinhardt, P. A. Baeuerle, P. Kufer, Tumor regression incancer patients by very low doses ofa T cell-engaging antibody. Science 321, 974-977 (2008).
21. W. W. Pang, E. A. Price, D. Sahoo, I. Beerman, W. J. Maloney, D. J. Rossi, S. L. Schrier, I. L. Weissman, Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc. Natl. Acad. Sci. U.S.A. 108, 20012-20017 (2011).
22. M. A. Kharfan-Dabaja, H. M. Lazarus, T. Nishihori, R. A. Mahfouz, M. Hamadani, Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: A focus on hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 19, 1006-1012 (2013).
23. S. Florian, K. Sonneck, A. W. Hauswirth, M. T. Krauth, G. H. Schernthaner, W. R. Sperr, P. Valent, Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk. Lymphoma 47, 207-222 (2006).
24. J. R. Fromm, Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma. Cytometry B Clin. Cytom. 80,91-99 (2011).
25. C. Krupka, P. Kufer, R. Kischel, G. Zugmaier, J. Bögeholz, T. Köhnke, F. S. Lichtenegger, S. Schneider, K. H. Metzeler, M. Fiegl, K. Spiekermann, P. A. Baeuerle, W. Hiddemann, G. Riethmüller, M. Subklewe, CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 123, 356-365 (2014).
26. G. S. Laszlo, C. J. Gudgeon, K. H. Harrington, J. Dell'Aringa, K. J. Newhall, G. D. Means, A. M. Sinclair, R. Kischel, S. R. Frankel, R. B. Walter, Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123, 554-561 (2014).
27. D. R. Le, D. C. Taussig, A. G. Ramsay, R. Mitter, F. Miraki-Moud, R. Fatah, A. M. Lee, T. A. Lister, J. G. Gribben, Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 114, 3909-3916 (2009).
28. S. R. Kuo, L. Wong, J. S. Liu, Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng. Des. Sel. 25, 561-569 (2012).
29. H. M. Gebel, L. K. Lebeck, S. C. Jensik, K. Webster, R. A. Bray, T cells from patients successfully treated with OKT3 do not react with the T-cell receptor antibody. Hum. Immunol. 26, 123-129 (1989).
30. E. J. Wherry, T cell exhaustion. Nat. Immunol. 12, 492-499 (2011).
31. S. Gill, S. K. Tasian, M. Ruella, O. Shestova, Y. Li, D. L. Porter, M. Carroll, G. Danet-Desnoyers, J. Scholler, S. A. Grupp, C. H. June, M. Kalos, Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343-2354 (2014).
32. A. Mardiros, C. Dos Santos, T. McDonald, C. E. Brown, X. Wang, L. E. Budde, L. Hoffman, B. Aguilar, W. C. Chang, W. Bretzlaff, B. Chang, M. Jonnalagadda, R. Starr, J. R. Ostberg, M. C. Jensen, R. Bhatia, S. J. Forman, T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against humanacute myeloidleukemia. Blood 122, 3138-3148 (2013).
33. I. Pizzitola, F. Anjos-Afonso, K. Rouault-Pierre, F. Lassailly, S. Tettamanti, O. Spinelli, A. Biondi, E. Biagi, D. Bonnet, Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28,1596-605 (2014).
34. S. Tettamanti, V. Marin, I. Pizzitola, C. F. Magnani, G. M. Giordano Attianese, E. Cribioli, F. Maltese, S. Galimberti, A. F. Lopez, A. Biondi, D. Bonnet, E. Biagi, Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br. J. Haematol. 161,389-401 (2013).
35. S. J. Busfield, M. Biondo, M. Wong, H. S. Ramshaw, E. M. Lee, S. Ghosh, H. Braley, C. Panousis, A. W. Roberts, S. Z. He, D. Thomas, L. Fabri, G. Vairo, R. B. Lock, A. F. Lopez, A. D. Nash, Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia 28,2213-2221 (2014).
36. M. Kügler, C. Stein, C. Kellner, K. Mentz, D. Saul, M. Schwenkert, I. Schubert, H. Singer, F. Oduncu, B. Stockmeyer, A. Mackensen, G. H. Fey, A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br. J. Haematol. 150, 574-586 (2010).
37. A. Frankel, J. S. Liu, D. Rizzieri, D. Hogge, Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelody splasia. Leuk. Lymphoma 49, 543-553 (2008).
38. L. Huang, L. S. Johnson, CD3-binding molecules capable of binding to human and non-human CD3, U.S. Patent. 20140099318 (2014).